Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2006064449) DETOXIFYING AND IMMUNITY-BOOSTER COMPOSITION
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2006/064449 International Application No.: PCT/IB2005/054183
Publication Date: 22.06.2006 International Filing Date: 12.12.2005
IPC:
A61K 39/00 (2006.01) ,A61K 31/015 (2006.01) ,A61K 39/07 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
01
Hydrocarbons
015
carbocyclic
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
02
Bacterial antigens
07
Bacillus
Applicants:
VAN DER WESTHUIZEN, Cornelis Floris [ZA/ZA]; ZA
Inventors:
VAN DER WESTHUIZEN, Cornelis Floris; ZA
Agent:
D M KISCH INC; P.O. Box 781218 2146 Sandton, ZA
Priority Data:
2004/1013015.12.2004ZA
Title (EN) DETOXIFYING AND IMMUNITY-BOOSTER COMPOSITION
(FR) COMPOSITION DETOXIFIANTE ET STIMULANT L'IMMUNITE
Abstract:
(EN) The invention relates to a detoxifying and immunity-booster treatment composition suitable for use in enhancing immunity in human subjects, the treatment composition comprising a base composition of microbes, and fulvic acid. In particular, the treatment composition may comprise approximately 50% by volume of the base composition added to approximately 50% by volume of fulvic acid. The base composition also may include humic acids, molasses, water and/or fish emulsion or extract. The fulvic acid may have a concentration of approximately 9%.
(FR) L'invention concerne une composition de traitement détoxifiante et stimulant l'immunité, conçue pour être utilisée dans l'amélioration de l'immunité chez des sujets humains, la composition de traitement comprenant une composition de base de microbes et de l'acide fulvique. Plus précisément, la composition de traitement peut comprendre approximativement 50 % en volume de la composition de base et approximativement 50 % en volume d'acide fulvique. La composition de base peut également comprendre des acides humiques, des molasses, de l'eau et/ou une émulsion ou un extrait de poisson. La concentration en acide fulvique peut être d'environ 9 %.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)